Compare Sana Biotechnology Inc (SANA) vs Upstart Holdings Inc (UPST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Upstart Holdings Inc — how do they compare? Sana Biotechnology Inc trades at $3.79 (market cap $1.13B), while Upstart Holdings Inc trades at $29.93 (market cap $2.91B). The key difference: Upstart Holdings Inc is far larger — about 2.6× Sana Biotechnology Inc's market cap, and Sana Biotechnology Inc is trading nearer its 52-week high, Upstart Holdings Inc nearer its low. Which is the better fit depends on your goals.
| SANA | UPST | |
|---|---|---|
Market Cap | $1.13B | $2.91B |
Sector | Health | Financials |
52-Week High | $5.92 | $73.76 |
52-Week Low | $2.68 | $24.22 |
Enterprise Value | $1.05B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.77, up 4.43% today, with a bullish technical signal from moving averages and ADX indicators. The company reported a net loss of $244.17 million for 2025, with negative cash flow from operations, but analyst consensus is strongly positive with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 average price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress driving future profitability, but high cash burn and negative ROE pose significant risks. Upside potential exists if pipeline milestones are met, supported by institutional optimism, though investors face volatility from earnings misses and funding needs.
Upstart trades at $29.23, down 3.24% today, with a bearish technical signal despite recent Q2 2026 earnings beat showing 42% revenue growth and return to GAAP profitability. The stock faces valuation compression concerns with a P/E of 57.48, while analyst consensus remains divided with a $47.20 price target suggesting significant upside potential from current levels.
The outlook balances strong AI-driven loan origination growth against persistent earnings misses and negative cash flow from operations. Key risks include high short interest at 27% and sensitivity to interest rate environment, though institutional sentiment appears cautiously optimistic given the 45% buy rating distribution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Upstart Holdings Inc
Upstart Holdings Inc provides credit services. The company provides a proprietary, cloud-based, artificial intelligence lending platform. The platform aggregates consumer demand for loans and connects it to the network of Upstart AI-enabled bank partners. The revenue of the company is primarily comprised of fees paid by banks.
Read more on UPST →
